Available treatments come short. Presently, there are twelve classes of T2D drugs approved by the FDA. The great majority of those involve modulation of insulin production and sensitivity, which over time tend to lose their effect. Atrogi’s concept is different and treats T2D independently of insulin signaling. The proposed solution meets accepted treatment guidelines, decreases disease associated complications that lead to morbidity and mortality, and will improve quality of life. This could be initial or combination therapy.
Atrogi has developed novel and patentable small molecules that through a unique pathway lowers blood glucose levels and treats T2D.
- Insulin independent – Unprecedented approach to T2D treatment
- Druglike – Our compound has the indicative characteristics needed for drug development
Druggable target – We can modulate our well known biological target with minimal side-effects
Predictive for humans – The model systems we use are accepted to be predictive for humans
The concept is scientifically and commercially innovative as it is independent of insulin signaling and offers an unprecedented approach to treat T2D.
Discover The Future
We are a multi-disciplinary team committed to focused and efficient drug development